USC 1233 INRA/Vetagro Sup, Mycotoxines et Toxicologie Comparée des Xénobiotiques, Veterinary School of Lyon, 1 av. Bourgelat, Marcy l'Etoile, France.
Arch Biochem Biophys. 2011 Nov;515(1-2):14-20. doi: 10.1016/j.abb.2011.08.010. Epub 2011 Aug 31.
Antivitamin K anticoagulants have been commonly used to control rodent pest all over the world for more than 50 years. These compounds target blood coagulation by inhibiting the vitamin K epoxide reductase (VKORC1), which catalyzes the reduction of vitamin K 2,3-epoxide to vitamin K. Resistance to anticoagulants has been reported in wild rat populations from different countries. From these populations, several mutations of the rVkorc1 gene have been reported. In this study, rat VKORC1 and its most frequent mutants L120Q-, L128Q-, Y139C-, Y139S- and Y139F-VKORC1 were expressed as membrane-bound proteins in Pichia pastoris and characterized by the determination of kinetic and inhibition parameters. The recombinant rVKORC1 showed similar properties than those of the native proteins expressed in the rat liver microsomes, validating the expression system as a good model to study the consequences of VKORC1 mutations. The determination of the inhibition parameters towards various antivitamin K anticoagulants demonstrated that mutations at Leu-120, Leu-128 and Tyr-139 confer the resistance to the first generation AVKs observed in wild rat populations.
抗维生素 K 抗凝剂在全世界范围内被广泛用于控制啮齿动物害虫已超过 50 年。这些化合物通过抑制维生素 K 环氧化物还原酶(VKORC1)来靶向血液凝固,VKORC1 催化维生素 K 2,3-环氧化物还原为维生素 K。来自不同国家的野生鼠种群中已经报道了对这些抗凝剂的耐药性。从这些种群中,已经报道了 rVkorc1 基因的几种突变。在这项研究中,VKORC1 及其最常见的突变体 L120Q-、L128Q-、Y139C-、Y139S-和 Y139F-VKORC1 作为膜结合蛋白在毕赤酵母中表达,并通过确定动力学和抑制参数进行了表征。重组 rVKORC1 表现出与在大鼠肝微粒体中表达的天然蛋白相似的特性,验证了表达系统作为研究 VKORC1 突变后果的良好模型。对各种抗维生素 K 抗凝剂的抑制参数的测定表明,亮氨酸 120、亮氨酸 128 和酪氨酸 139 的突变赋予了野生鼠种群中观察到的第一代 AVKs 的耐药性。